Abstract
Sarcopenic obesity (SO) is a clinical condition characterized by the coexistence of reduced muscle mass and function along with obesity. The prevalence of SO increases with age, posing a threat to individuals’ physical independence. SO is particularly associated with a loss of physical abilities, a higher risk of falls, decreased quality of life, and increased mortality rates in older adults. Additionally, metabolic disorders related to obesity exacerbate the clinical severity of this condition. Among the screening tools used for SO, SARC-F + BMI (Strength, Ambulation, Rising from a Chair, Stair Climbing and History of Falling + Body Mass Index) and SARC-CaLF + PBF (SARC-F Combined with Calf Circumference + Percentage of Body Fat) stand out. However, both methods have limitations. Furthermore, screening with SARC-CaLF + PBF may require devices that are not suitable for use in primary care. This complicates the screening, early treatment, and determination of SO prevalence in the community. Therefore, it is necessary to develop sensitive screening tools suitable for use in primary care.
References
- Batsis, J. A., & Villareal, D. T. (2018). Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nature reviews. Endocrinology, 14(9), 513–537. https://doi.org/10.1038/s41574-018-0062-9
- Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., Bauer, J. M., Boirie, Y., Cruz-Jentoft, A. J., Dicker, D., Frara, S., Frühbeck, G., Genton, L., Gepner, Y., Giustina, A., Gonzalez, M. C., Han, H. S., Heymsfield, S. B., Higashiguchi, T., Laviano, A., … Barazzoni, R. (2022). Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement. Obesity facts, 15(3), 321–335. https://doi.org/10.1159/000521241
- Petermann-Rocha, F., Balntzi, V., Gray, S. R., Lara, J., Ho, F. K., Pell, J. P., & Celis-Morales, C. (2022). Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. Journal of cachexia, sarcopenia and muscle, 13(1), 86–99. https://doi.org/10.1002/jcsm.12783
- Wei, S., Nguyen, T. T., Zhang, Y., Ryu, D., & Gariani, K. (2023). Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management. Frontiers in endocrinology, 14, 1185221. https://doi.org/10.3389/fendo.2023.1185221
- Zhuang, M., Wang, L., He, X., Ma, L., Song, Y., & Chen, N. (2024). Prevalence of sarcopenic obesity: comparison of different diagnostic criteria and exploration of optimal screening methods. BMC geriatrics, 24(1), 799. https://doi.org/10.1186/s12877-024-05378-3
Abstract
Sarkopenik obezite (SO) azalmış kas kütlesi ve fonksiyonunun obezite ile birlikte görülmesiyle karakterize olan klinik bir durumdur. Yaşla birlikte artan SO prevalansı, bireylerin fiziksel bağımsızlığını tehdit eder. SO özellikle ileri yaşta fiziksel yetenek kaybı, düşme riski, yaşam kalitesinde azalma ve artmış ölüm oranlarıyla ilişkilidir. Sarkopeniye ek olarak obeziteye bağlı görülen metabolik bozukluklar hastaların kliniğini daha da kötüleştirmektedir. SO için kullanılan tarama araçları arasında SARC-F + BMI (Strength, Ambulation, Rising from a Chair, Stair Climbing and History of Falling + Body Mass Index) ve SARC-CaLF + PBF (SARC-F Combined with Calf Circumference + Percentage of Body Fat) öne çıkmaktadır. Ancak her iki yöntemin de sınırlılıkları bulunmaktadır. Ayrıca SARC-CaLF + PBF ile taramada birinci basamakta kullanımı uygun olmayan cihazlara ihtiyaç duyulabilmektedir. Bu durum SO’nun taranmasını, erken tedavisini ve toplumdaki sıklığının belirlenmesini zorlaştırmaktadır. Bu nedenle birinci basamakta kullanıma uygun hassas tarama araçlarının geliştirilmesi gerekmektedir.
Keywords
Birinci basamak sağlık hizmetleri Geriatrik popülasyon Kas kütlesi Sarkopenik obezite Tarama araçları
References
- Batsis, J. A., & Villareal, D. T. (2018). Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nature reviews. Endocrinology, 14(9), 513–537. https://doi.org/10.1038/s41574-018-0062-9
- Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., Bauer, J. M., Boirie, Y., Cruz-Jentoft, A. J., Dicker, D., Frara, S., Frühbeck, G., Genton, L., Gepner, Y., Giustina, A., Gonzalez, M. C., Han, H. S., Heymsfield, S. B., Higashiguchi, T., Laviano, A., … Barazzoni, R. (2022). Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement. Obesity facts, 15(3), 321–335. https://doi.org/10.1159/000521241
- Petermann-Rocha, F., Balntzi, V., Gray, S. R., Lara, J., Ho, F. K., Pell, J. P., & Celis-Morales, C. (2022). Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. Journal of cachexia, sarcopenia and muscle, 13(1), 86–99. https://doi.org/10.1002/jcsm.12783
- Wei, S., Nguyen, T. T., Zhang, Y., Ryu, D., & Gariani, K. (2023). Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management. Frontiers in endocrinology, 14, 1185221. https://doi.org/10.3389/fendo.2023.1185221
- Zhuang, M., Wang, L., He, X., Ma, L., Song, Y., & Chen, N. (2024). Prevalence of sarcopenic obesity: comparison of different diagnostic criteria and exploration of optimal screening methods. BMC geriatrics, 24(1), 799. https://doi.org/10.1186/s12877-024-05378-3
Details
| Primary Language | English |
|---|---|
| Subjects | Clinical Sciences (Other) |
| Journal Section | Letter to Editor |
| Authors | |
| Publication Date | November 28, 2025 |
| Submission Date | January 2, 2025 |
| Acceptance Date | April 14, 2025 |
| Published in Issue | Year 2025 Volume: 10 Issue: 4 |
